Annals of Hematology

Papers
(The H4-Index of Annals of Hematology is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry126
Hematologic disorders associated with COVID-19: a review59
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes54
Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies52
Impact of rituximab on COVID-19 outcomes47
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working 46
Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy44
Hematologic changes predict clinical outcome in recovered patients with COVID-1942
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the Ge36
Hemolytic anemia in COVID-1935
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes33
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for33
Castleman disease and TAFRO syndrome32
Concise review: how do red blood cells born, live, and die?32
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation30
Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database30
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data30
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey30
Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation30
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial28
Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?28
ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies26
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives25
Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA012525
The emerging therapeutic landscape of relapsed/refractory multiple myeloma25
0.11612391471863